Ecuador
Tuberculosis profile
Population  2013 16 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.32 (0.18–0.49) 2 (1.2–3.1)
Mortality (HIV+TB only) 0.36 (0.3–0.43) 2.3 (1.9–2.7)
Prevalence  (includes HIV+TB) 13 (6.9–21) 82 (44–131)
Incidence  (includes HIV+TB) 8.8 (7.9–10) 56 (50–64)
Incidence (HIV+TB only) 1.2 (1.1–1.4) 7.9 (7.1–9)
Case detection, all forms (%) 60 (52–66)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 4.9 (3.5–6.7) 26 (23–29)
MDR-TB cases among notified pulmonary
TB cases
200 (140–270) 140 (120–160)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 3 741   301
Pulmonary, clinically diagnosed 324   0
Extrapulmonary 911   0
       
Total new and relapse 5 277    
Previously treated, excluding relapses 232    
Total cases notified 5 509    
Among 5 277 new and relapse cases:
234 (4%) cases aged under 15 years; male:female ratio: 1.9
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 55 (1%) 123 (23%) 190
Laboratory-confirmed RR-/MDR-TB cases     117
Patients started on MDR-TB treatment     95
TB/HIV 2013 Number (%)
TB patients with known HIV status 4 970 (90)
HIV-positive TB patients 698 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 698 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 75
Previously treated cases, excluding relapse, registered in 2012 43
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 56
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.1
Culture (per 5 million population) 8.3
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 5
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 4.6
% Funded domestically 97%
% Funded internationally 3%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-27 Data: www.who.int/tb/data